Customer Center
Login | Register
 
 

Clinical

Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
 
Read More

Research & Applied Markets

Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
 
Read More

Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
 
Learn More

Luminex® Blog

Leading Pediatrics Hospital Finds Rapid Testing Reduces Unnecessary Use of Antibiotics

In a five-year study, VERIGENE® BC-GP Test shrinks time to results by as much as 24 hours

In a new publication, medical professionals from Children’s Hospital Los Angeles and the University of Southern California report results from a comprehensive five-year study of the VERIGENE® Gram-Positive (BC-GP) Blood Culture Test. They found that the “[VERIGENE] BC-GP panel demonstrated excellent performance” and that its reliable detection of genes conferring drug resistance allows healthcare providers to “confidently de-escalate antimicrobial therapy” when appropriate, according to the paper.

Continue Reading >

xMAP® Technology Overview

 
Luminex xMAP® Technology Overview

 

xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.

Watch more videos >

Luminex on Twitter


The risk of death from #sepsis increases by as much as 7.6% for every hour that appropriate treatment is delayed. L… https://t.co/BDDzAhq7Dt
h J R
Medical professionals from @ChildrensLA and @USC reported the results from a 5-year #study, in what could be the la… https://t.co/LowKYpC6bM
h J R
A recent study by the Perelman School of Medicine at @PennMedicine found that a universal flu #vaccine that protect… https://t.co/4YeQLDKAv4
h J R

Latest News

September 11
Luminex Corporation Declares Third Quarter Cash Dividend

September 6
Luminex Corporation to Present at the Morgan Stanley 16th Annual Global Healthcare Conference

August 6
Luminex Corporation Reports Second Quarter 2018 Financial Results

July 13
Luminex Corporation Second Quarter Earnings Release Scheduled for August 6, 2018

June 13
Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay

Events

Microbe UK
21-23 September
Sheffield, UK

World Vaccine Congress
29-31 October
Lisbon, Portugal

xMAP® Connect Amsterdam
6-7 November
Amsterdam, Netherlands